The new era (post COVID) challenges are still beyond full understanding, never before the world has
acted as fast in terms of medical treatment, to the point of obtaining multiple vaccines and
therapeutic treatments in less than two years. The responds from governments and privet sector
easily exceeds the 2018-2028 landscape capabilities. The more notable limitations since COVID
beginning (late 2019) are the raw materials and production footprints. Both challenges are in the
scope and current plans of the the big pharma companies and governments. The consequences of these
new capabilities create the perfect scenario for SAGA’s origin: “With that many new facilities and
low chances to fail, the future of any company need to be run and operate by capable and knowable
people”.